Statistically significant differences compared with Placebo MDI were noted at almost all doses for the secondary FEV1 parameters ( P .049 ) except 24-hour trough FEV1 at 28.8 g. All doses were safe and well tolerated in this study ; the most frequently reported adverse event was dry mouth ( 0-14 .3 % across doses ; 9.5 % for Placebo MDI , and 9.1 % for TIO ) .